(Resistance to Targeted Anti-Cancer Therapeutics (15)) 1st ed. 2018 Edition

by Yosef Yarden (Editor), Moshe Elkabets (Editor)

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.